Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Veracyte, Inc.NASDAQ: VCYT

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity rises 13.7% from a year ago

Total equity stood at $1.39B at the end of Q2 FY2026, up 13.7% from a year earlier and up 3.3% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.

Context

  • Total equity amounted to 93.4% of total assets at the end of Q2 FY2026, up 2.6 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +13.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.39B+3.3% QoQ
Last fiscal yearDec 2025
$1.31B+11.4% YoY
Year agoJun 2025
$1.22B+13.7% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.7%——
1 year+11.4%——
3-year CAGR+6.8%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
1.31B USD
Year-over-year change
+11.4%
4-year CAGR
+4.5%

Total Equity vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's Jun 2026 total equity of $1.39B is the highest of the 10 companies compared; the peer median is $254.77M.
  • Its year-over-year change of +13.7% is the 4th highest of 10, against a peer median of -8.0%.
  • Total equity amounts to 93.4% of total assets for VCYT, versus a peer median of 50.7%.
VCYT Competitors Peer median
Total Equity for VCYT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VCYTVeracyte, Inc.Jun 2026$1.39B +13.7%+6.8%93.4%
NEONeoGenomics, Inc.Jun 2026$785.73M -8.0%-5.7%58.1%
BLLNBillionToOne, Inc.Jun 2026$536.81M +217.3%—73.6%
CSTLCastle Biosciences, Inc.Mar 2026$461.42M +4.8%+5.7%84.2%
MYGNMyriad Genetics, Inc.Mar 2026$337.4M -52.1%-25.4%50.1%
PSNLPersonalis, Inc.Mar 2026$254.77M +22.9%+6.2%78.3%
WGSGeneDx Holdings Corp.Jun 2026$244.22M -11.9%+6.7%50.7%
BDSXBiodesix, Inc.Mar 2026$9.13M -17.4%—9.6%
IMDXInsight Molecular Diagnostics Inc.Mar 2026-$10.69M -204.6%—26.4%
GHGuardant Health, Inc.Sep 2026-$275.9M +22.2%—14.6%
Peer median (excluding VCYT) $254.77M-8.0%+5.7%50.7%

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents173.2M154.25M216.45M239.09M362.58M
Short-term Investments3.96M24.61M050.35M50.31M
Net Receivables41.46M44.02M40.38M46.53M44.66M
Inventory11.23M14.29M16.13M21.75M20.55M
Other Current Assets(3.96M)11.47M12.66M14.55M10.28M
Total Current Assets243.1M248.64M285.62M372.27M488.38M
Property, Plant & Equipment (Net)31.14M30.86M30.86M71.14M58.79M
Goodwill707.9M695.89M702.98M745.8M767.15M
Intangible Assets202.73M174.87M88.59M102.3M89.15M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.95M6.17M6.85M8.53M2.55M
Total Non-current Assets944.72M907.79M829.29M927.77M917.64M
Total Assets1.19B1.16B1.11B1.3B1.41B
Account Payables12.36M11.91M12.94M8.63M4.59M
Short-term Debt1.13M0000
Tax Payables00000
Deferred Revenue4.65M2.61M2.01M1.67M1.16M
Other Current Liabilities33.71M36.88M29.19M47.6M28.79M
Total Current Liabilities64.15M62.61M61.24M78.63M59.94M
Long-term Debt00000
Deferred Tax Liabilities5.59M4.53M734K1.23M646K
Deferred Revenue (Non-current)343K0000
Other Non-current Liabilities7.13M3.43M1.3M972K257K
Total Non-current Liabilities27.16M18.61M9.56M45.44M36.51M
Total Liabilities91.31M81.22M70.8M124.07M96.44M
Common Stock71K72K73K78K79K
Retained Earnings(357.16M)(393.72M)(468.12M)(443.98M)(377.63M)
Accumulated OCI(15.08M)(31.35M)(24.02M)(36.09M)(8.21M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.1B1.08B1.04B1.18B1.31B
Total Debt18.85M14.72M12.63M50.74M39.65M
Net Debt(154.34M)(139.53M)(203.82M)(188.35M)(322.92M)

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.